Page last updated: 2024-09-05

hmr 1766 and Cardiac Hypertrophy

hmr 1766 has been researched along with Cardiac Hypertrophy in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dahal, BK; Dumitrascu, R; Eickels, Mv; Fuchs, B; Ghofrani, HA; Grimminger, F; Hackemack, S; Medebach, T; Mittal, M; Pullamsetti, SS; Savai, R; Schermuly, RT; Seeger, W; Weissmann, N	1

Other Studies

1 other study(ies) available for hmr 1766 and Cardiac Hypertrophy

Article	Year
The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. American journal of physiology. Lung cellular and molecular physiology, 2009, Volume: 297, Issue:4 Topics: Animals; Cardiomegaly; Cyclic GMP; Guanylate Cyclase; Hemodynamics; Hypertension, Pulmonary; Hypoxia; Mice; Myocytes, Smooth Muscle; ortho-Aminobenzoates; Pulmonary Artery; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Sulfonamides; Superoxides; Vasoconstriction	2009

Article

Year

The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice.

American journal of physiology. Lung cellular and molecular physiology, 2009, Volume: 297, Issue:4

Topics: Animals; Cardiomegaly; Cyclic GMP; Guanylate Cyclase; Hemodynamics; Hypertension, Pulmonary; Hypoxia; Mice; Myocytes, Smooth Muscle; ortho-Aminobenzoates; Pulmonary Artery; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Sulfonamides; Superoxides; Vasoconstriction

2009